Clinical trials for Lymphoma

93 currently recruiting clinical trials

Early Access Lymphoma
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required number of previous lines of therapy
1
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Hoffmann-La Roche
Early Access Lymphoma
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required number of previous lines of therapy
2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
1 recruiting site
Hoffmann-La Roche
Phase 3 Lymphoma CLL & Richter's syndrome #NCT06104566 #2023-508005-24-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required number of previous lines of therapy
1
Required previous treatments
Targeted therapy
Excluded previous treatments
Systemic Treatment-Naive
12 recruiting sites
Ascentage Pharma Group Inc.
Phase 3 Lymphoma #NCT06006117 #2022-501810-77-00
Required histologic types
B cell lymphoma
Required histologic sub types
Marginal zone lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Targeted therapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive Bispecific T-cell engager antibodies Allogeneic stem cell transplant
23 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3 Lymphoma CLL & Richter's syndrome #NCT05254743 #2023-507699-38-00
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia)
Required histologic sub types
Lymphocytic lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
10 recruiting sites
Loxo Oncology
Phase 3 Lymphoma #NCT06284122 #2023-505436-35-00
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required renal function statuses
30-50 ml/min < 30 ml/min
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Allogeneic stem cell transplant Radiotherapy
37 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3 Lymphoma #NCT06911502
Required histologic types
B cell lymphoma
Required histologic sub types
Follicular lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Monoclonal antibodies
5 recruiting sites
Celgene
Phase 3 Lymphoma #NCT06091865 #2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
18 recruiting sites
Regeneron Pharmaceuticals
Phase 3 Lymphoma #NCT06091865 #2022-502785-25-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None
Required immunophenotypic profiles
CD20
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
18 recruiting sites
Regeneron Pharmaceuticals
Phase 3 Lymphoma #NCT06717347 #2024-515566-13-00
Required histologic types
B cell lymphoma
Required histologic sub types
Large B cell lymphoma
Required central nervous system lesions
None Treated / Controled
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
14 recruiting sites
Merck Sharp & Dohme LLC